Targeting Drivers of Resistance in Advanced Prostate Cancer: Evolving towards Precision Oncology

Martin E. Gleave

Companion diagnostics and personalized medicine in prostate cancer

Takayuki Goto

A deep dive in liquid biopsies for non-invasive prostate cancer markers

Jun Luo

Value of dynamic contrast-enhanced imaging in computeraided diagnosis of prostate cancer on multiparametric magnetic resonance imaging

You Matsuoka

Computer-Aided Diagnosis based on Deep Convolutional Neural Network system using novel 3D MRI sequences for high-grade prostate cancer

Ryo Oka

Prognostic comparison after robotic-assisted radical prostatectomy for prostate cancer diagnosed by MRI-US fusion biopsy versus conventional biopsy

Kazumi Kamoi

Urine Spermine and multiparametric MRI for prediction of prostate cancer in Japanese men

Shuuji Isotani

The relationship between gut microbiota and prostate cancer

Makoto Matsushita

MRI-TRUS fusion image-navigated robot-assisted radical prostatectomy for negative surgical margins in patients with capsule contact localized prostate cancer

Sunao Shoji

Targeted focal cryotherapy for clinically significant localized prostate cancer using Intraoperative Navigation with Augmented/Mixed Reality

Atsuko Fujihara

Equivalence of immunological response to COVID-19 vaccination in prostate cancer patients

Naotaka Gunge

A translational inhibitor, homoharringtonine, induces rapid apoptosis and therapeutic effect on prostate cancer xenograft models

Seiji Arai

Patterns of disease progression revealed by PSMA-PET in men with biochemical recurrence after prostate cancer radiotherapy

Koji Hatano

Prognostic significance of PSA doubling time among Japanese non-metastatic castration-resistant prostate cancer patients: a JUOG multi-institutional study

Shinichi Sakamoto

Totarol could enhance the apoptosis of metastatic androgen-insensitive human prostate cancer PC3 cells: The first in-vitro study

Che Hsueh Yang

Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy

Souichirou Yoshida

Oncological outcomes in the metastatic low tumorburden prostate cancer are not significantly different from the locally advanced (T4 or N1) prostate cancer

Toshikazu Tanaka

The feasibility of molecular profiling of prostate tissue samples obtained from patients with metastatic castration-resistant prostate cancer

Takayuki Sumiyoshi

Potential relationship between the prevalence of JCPyV or BKPyV and prostate cancer

Ya-che Lee

ESS2 controls prostate cancer progression through recruitment of chromodomain helicase DNA binding protein 1

Sayuri Takahashi

Nomograms to predict biochemical recurrence-free survival in high-risk prostate cancer patients after carbonion radiotherapy and androgen deprivation therapy

Takanobu Utsumi

Genome-wide association study (GWAS) of prostate cancer (PCa) in Taiwanese population

Ming Ru Lee

GDPP is a novel blood biomarker in bone metastasis of prostate cancer by fueling the vicious cycle

Gaku Yamamichi

Refinement of the prognostic model for de-novo metastatic hormone-naive prostate cancer

Hiroshi Fujiwara

Availability of [-2]proPSA related indices in a diagnosis of prostate cancer

Yoshitaka Sekine

Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA): A novel tool for detecting prostate cancer in PSA levels under 10 ng/mL

Masanori Hasegawa

Expression of ST3GAL2-associated markers in sera of patients with castration-resistant prostate cancer

Seiichi Saito

Diagnostic tool combined with nomogram and AI deep learning to select indication for pelvic lymph node dissection in robot-assisted radical prostatectomy

Yuki Yoshida

Diagnostic potential of FDG-PET/MRI for detection of index tumor in prostate cancer with PSMA lowexpression and without multiparametric MRI detection

Kei Yaginuma

Genomic features in metastatic hormone-sensitive prostate cancer (mHSPC) with or without intraductal carcinoma of the prostate (IDC-P) in Japanese patients

Masashi Kato

Combination of deep learning and ensemble machine learning using intraoperative video images strongly predicts recovery of urinary continence after RARP

Wataru Nakamura

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Toshiki Oka

A National Questionnaire Survey of Japanese Urologists on Active Surveillance for Low- and Intermediate-Risk Prostate Cancer

Takuma Kato

Screen for predictive factor of the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients

Takashi Ueda

A prospective study of MRI-ultrasound fusion-guided ultrafocal high-dose-rate brachytherapy (HDR-BT) for primary localized prostate cancer

Yoshiyuki Miyaji

Mid-term outcomes of Retzius-sparing RARP

Kimitoshi Saito

Personalized Treatment for Castration-Resistant Prostate Cancer by Cancer Gene Panel Test

Tetsutarou Hayashi

PSA doubling time predicts the efficiency of site-directed therapy for non-metastatic or oligometastatic castrationresistant prostate cancer

Taketo Kawai

Positive resection margin and PSA recurrence in radical prostatectomy based on the Ehime Prefecture database

Iku Ninomiya

APC mutation contributes to neuroendocrine differentiation and poor overall survival in metastatic prostate cancer patients

Yuto Baba

The effect of a reduced dose of apalutamide on skinrelated adverse events in advanced prostate cancer

Kyo Togashi

Clinical implications of intraductal carcinoma of the prostate (IDC-P) and recent advances in precision medicine in prostate cancer

Eri Banno

Current topics on morphological and molecular pathology of prostate cancers

Kosuke Miyai

Molecular biomarkers to guide active surveillance for prostate cancer: The promise and the perils

David M. Berman

Prostate Cancer Screening Pitfalls - From an Epidemiologist's Perspective

Tomio Nakayama

Pitfalls on screening for prostate cancer: Future perspectives on risk-stratified PSA screening system

Kazuto Ito

The significance of active surveillance for early-stage prostate cancer

Takuma Kato

Current status and future prospective of focal therapy for localized prostate cancer

Sunao Shoji

IMRT by Helical Tomotherapy for prostate cancer increases subsequent risk of bladder cancer at single institution: A propensity score matched analysis

Fumio Tsukuda

Genome-wide association study identified genetic polymorphisms associated with prognosis in primary androgen deprivation therapy for advanced prostate cancer

Masaki Shiota

Suppression of AR signaling promotes prostate cancer metastasis via the CCL20-CCR6 pathway

Hiroshi Kano

NEUROD1 positive neuroendocrine prostate cancer acquires Cisplatin resistance through MUC1/cMyc axis

Yota Yasumizu

Combined inhibition of PARP and ATR is synthetic lethal in CDK12 aberrant prostate cancer

Yuki Kamiyama

Systematic mapping of radiosensitivity and gene interactions identifies a novel therapeutic target in prostate cancer

Koji Hatano

Estimating copy number using next-generation sequencing to determine BRCA2 deletion status and to expect prognosis in clinically localized prostate cancer

Takuhisa Nukaya

Identification of c-Met as a novel target of gammaglutamylcyclotrasnferase in a prostate cancer cell line

Yumiko Saito

Novel magnetic nanoparticle with carbon nanohorn for the hyperthermia of castration-resistant prostate cancer

Takashi Nagai

Impact of multiple gene mutations on PARP Inhibitor sensitivity

Takuya Tsujino

Dependence on glycolysis related to alteration of FOXA1 cistrome in castration-resistant prostate cancer

Manato Kanesaka

Targeting ribonuclease H2 activity as a potential therapeutic strategy for castration-resistant prostate cancer

Naoki Kimura

Truth of a Prostate Cancer Patient - What I learned from supporting prostate cancer patients -

Tsutomu Takeuchi

What doctors should consider now in prostate cancer treatment

Tomomi Nakagawa

Visualising Treatment with PSMA Radioligand Therapy: the latest treatment for metastatic prostate cancer

Michael S. Hofman

New modified technique of Hydrogel spacer implantation for prostate cancer The novel method for separation at the apex level under real-time ultrasound guidance

Tsukasa Narukawa

Prostate and Metastasis Diffusion Volume Based on Apparent Diffusion Coefficient as a Prognostic Factor in Hormone-naïve Prostate Cancer

Motohiro Fujiwara

Clinical significance and risk factors of pathological upgrading in prostate cancer patients undergoing robotassisted radical prostatectomy

Yuta Takeshima

Enzalutamide prior to radium-223 resulted in overall survival benefit in mCRPC patients compared to abiraterone- a retrospective study

Hao Xiang Chen

Comparison of Dosage and Clinical Outcome of Ra-223 in mCRPC: Real World Data from a Medical Center in Southern Taiwan

Sheng Min Tsai

Comparison of chemotherapy and Androgen Receptor Targeted Agents as sequencing treatment in castration resistance prostate cancer

Mu-yao Tsai

Serum testosterone bounce predicts the favorable prognosis in prostate cancer patients treated with degarelix acetate

Shinichi Sakamoto

New option of darolutamide in addition to ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer: Japanese subgroup analysis of ARASENS

Motohide Uemura

Clinical Investigation of abiraterone therapy for high-risk metastatic hormone-sensitive prostate cancer

Satoshi Muraoka

Usefulness of CAB therapy with GnRH antagonist for bone metastatic prostate cancer with pretreatment prostatespecific antigen level >50 ng/ml (second report)

Takeshi Kashiwabara

Comparison of ARAT therapy and bicalutamide in men with metastatic hormone sensitive prostate cancer: a report of multi-center retrospective Study

Natsuo Kimura

Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy

Daichi Sasaki

Abiraterone and olaparib vs abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer: PROpel Japanese subgroup analysis

Mikio Sugimoto

Efficacy of enzalutamide for chemo-naïve nmCRPC

Tatsuya Shimomura

Outcome and Prognostic Factors of Enzalutamide in Castration-resistant Prostate Cancer at Kumamoto Chuo Hospital

Shinsuke Hamada

A Study of Enzalutamide Serum Concentrations and Safety in Patients with Castration-Resistant Prostate Cancer

Taro Iguchi

Clinical outcomes in nonmetastatic castration-resistant prostate cancer treated with androgen receptor-axistargeted agent therapy

Ryo Fujiwara

Usefulness of hochuekkito for frailty patients with metastatic prostate cancer- focusing on bone mineral density, muscle strength, and urinary function -

Hitoshi Oh-oka

Effects of androgen deprivation therapy on cognitive function in Japanese patients with prostate cancer

Yutaka Yamamoto

Dose reduction of enzalutamide does not affect PSAprogression-free survival in patients with castrationresistant prostate cancer

Yukiyoshi Hirayama

Bone mineral density loss during androgen-deprivation therapy for prostate cancer patients and the effects of denosumab

Ojiro Tokairin

Characteristics of elderly prostate cancer patients diagnosed by prostate specific antigen screening

Yasuyuki Sakai

Comprehensive geriatric assessment (CGA) of patients prior initial prostate cancer treatment

Hiroshi Nagae

Compensated and primary hypogonadism associated with diagnosis of ISUP grade groups 3-5 prostate cancer

Kazuki Kobayashi

Examination of predictors of prostate cancer detection in transurethral benign prostatic hyperplasia surgery

Hiromasa Shiraishi

Inflammatory signaling in prostate cancer: IL1β production by infiltrating myeloid cells promotes local invasion

Charles L. Sawyers

Contribution of nerve to progression of prostate cancer

Yusuke Goto

The challenges of prostate cancer screening in an Asian country

Teng Aik Ong

Financial toxicity associated with contemporary treatment for prostate cancer

Toshitaka Shin

Treatment strategy for older patients with high-risk prostate cancer

Shintaro Narita

The role of the RARP for clinically localized high-risk prostate cancer

Masaki Shimbo

Low-dose late brachytherapy for high-risk localized or locally advanced prostate cancer

Kouji Izumi

Intensity-modulated radiation therapy (IMRT) for clinically localized high-risk prostate cancer: Current evidence and future perspective

Rihito Aizawa

Senescence in cancer and myeloid cells control prostate cancer progression

Andrea Alimonti

Development of novel therapeutic technology for MRIvisible prostate cancer lesion

Osamu Ukimura

Significance of atypical nodules upgraded to category 3 by abnormal DWI finding in PI-RADS version 2.1 for prostate cancer diagnosis

Shintaro Asai

Association of minimum apparent diffusion coefficient with grade group of prostate cancer in the transition zone

Ashita Ono

Prognostic significance of pathological factors among localized prostate cancer patients receive robot assisted prostatectomy

Mai Morikawa

How do the Cribriform component and IDC-P affect prognosis in patients with metastatic prostate cancer?

Akiyuki Yamamoto

Retrospective analysis of carbon ion radiotherapy for nonmetastatic castration-resistant prostate cancer

Hidemasa Kawamura

Outcomes of hypofractionated radiotherapy for localized prostate cancer at Tane general hospital

Kota Iida

Ultra-hypofractionated radiotherapy with Stereotactic Body Radiation Therapy (SBRT) for localized prostate cancer

Sao Katsumura

Oncological outcomes, toxicity, quality of life, and second primary cancers in patients treated with intensitymodulated radiotherapy for prostate cancer

Yasushi Nakai

Testosterone recovery after completion of hormone therapy combined with irradiation for prostate cancer

Jun Niino

An analysis of I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer: TRIP trial

Hiroshi Yaegashi

Biochemical recurrence predictor of prostate brachytherapy with iodine-125 permanent seed implantation for localized prostate cancer

Yasuto Yagi

Relationship between the urethral dose distribution and quality of life in high-dose rate brachytherapy for prostate cancer

Takahito Wakamiya

Clinical benefits of SpaceOAR hydrogel spacer for prostate cancer patients treated with low-dose-rate (LDR) brachytherapy

Tomoharu Fukumori

Is external beam radiotherapy combination a risk factor for bladder cancer in patients with prostate cancer treated by brachytherapy?

Takafumi Minami

Secondary bladder cancer after radiotherapy for prostate cancer

Hideyuki Terao

The second bladder cancer incidence in prostate cancer patients treated with low-dose-rate brachytherapy

Masatsugu Miyashita

Applying the Spirit of the First Penguin to Tailor Metastatic Hormone Sensitive Prostate Cancer Therapy

Christopher J. Sweeney

Japan registry to observe clinical outcomes of patients with high-risk metastatic hormone-naïve prostate cancer (J-ROCK study): Interim analysis at 3 years

Kiyohide Fujimoto

Evaluation of circulating tumor DNA-based genomic alterations in Japanese mCSPC patients treated with apalutamide: interim analysis of CUARTET study

Hirotsugu Uemura

Prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormonesensitive prostate cancer (mHSPC) from ARASENS

Hiroyoshi Suzuki

Local therapy for metastatic prostate cancer: clinical questions and unmet needs

Naoki Terada

Clinical questions and unmet needs in mHSPC

Takahiro Kimura

Current status and future perspectives on therapies for metastatic and non-metastatic CRPC

Kohei Hashimoto

CQs and unmet needs for personalized prostate cancer treatment

Takeo Kosaka

Initial experience of targeted focal therapy with microwave coagulation for localized prostate cancer

Munehiro Ohashi

Initial experience of MRI-guided transurethral ultrasound ablation for localized prostate cancer

Masayoshi Miura

Trial for the clinical application of luteolin for chemopreventive study of patients with prostate cancer

Taku Naiki

Prognostic factors of patients with metastatic CRPC treated by radium-223

Mitsuhisa Nishimoto

Trends in the use of local intervention and its impact on oncological outcomes for metastatic castration-sensitive prostate cancer

Osamu Soma

Comparison of extended and limited pelvis lymph node dissection with radical prostatectomy for high-risk prostate cancer

Naoto Kamiya

Prognostic benefit of neoadjuvant therapy compared with extended pelvic lymph node dissection in patients with high-risk prostate cancer treated with RARP

Takuya Oishi

Oncological safety of nerve-sparing RARP in intermediateand high-risk prostate cancer patients: A retrospective multicenter study (the MSUG94 group)

Masahiro Toide

Prognostic significance of positive surgical margin in patients with pathologically organ-confined prostate cancer treated with robotic surgery

Jun Nakashima

Nomogram predicting for Locally Advanced Prostate Cancer at Robot-Assisted Radical Prostatectomy (the MSUG94 group)

Makoto Kawase

Predictors of castration-resistant prostate cancer after radical prostatectomy for high-risk prostate cancer

Takato Nishino

Docetaxel versus Abiraterone for Metastatic Hormone-Sensitive Prostate Cancer with Focus on Efficacy of Sequential Therapy

Takafumi Yanagisawa

Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients

Kai Ozaki

The impact of docetaxel and cabazitacel side effects on the duration of chemotherapy treatment for castrationresistant prostate cancer

Yuma Kujime

Cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer: results from the KPUM Prostate Cancer Study Group

Takumi Shiraishi

Clinical outcomes in patients with mCRPC treated with docetaxel rechallenge after upfront docetaxel for highvolume mCSPC: A case series

Kenichi Hata

The impact of PSA response at 3 months after hormonal therapy on prognosis in patients with metastatic hormone-sensitive prostate cancer

Shingo Hatakeyama

Prostate-specific antigen change rate after treatment of androgen receptor-axis-targeted agents and prognosis of castration-resistant prostate cancer

Kenta Onishi

Remission depth in metastatic hormone-sensitive prostate cancer is associated with prognosis in patients with iPSA values above 100 ng/ml

Takeshi Azuma

Prognostic factors and PSA kinetics in Japanese patients with metastatic hormone-sensitive prostate cancer (mHSPC) initially treated with bicalutamide CAB

Yuu Tashiro

Investigation of super responders to drug therapy for metastatic prostate cancer

Keita Takimoto

Serum testosterone as a biomarker for patient selection for flutamide use in metastatic castration resistant prostate cancer treatment

Tetsuya Shindo

Pilot study of an artificial intelligence-based deep learning algorithm to predict hormone sensitivity for metastatic hormone-naïve prostate cancer

Wataru Nakata

Biology and usefulness of [-2]proPSA as a prognostic marker in CRPC patients

Yoshiyuki Miyazawa

Tumor diffusion volume according to apparent diffusion coefficient values as a prognostic factor for castrationresistant prostate cancer

Takahiko Soma

The impact of nerve-sparing on surgical margin and biochemical recurrence after robot-assisted radical prostatectomy in patients with localized prostate cancer

Seiichi Katou

Comparison of voiding function after RARP versus IMRT in Japanese patients diagnosed with localized prostate cancer: Interim analysis of a prospective study

Goshi Kitano

Osteoblast-derived exosomes exert the osteoblastic and tumor-suppressive functions in prostate cancer

Kagenori Ito

Efficacy of combined CD73 and A2aR blockade in mouse Pten-deficient prostate cancer

Marco Develasco

Use of a preclinical prostate cancer model to assess molecular and immune responses to androgen receptor signaling axis blockade

Hirotsugu Uemura

Prolyl isomerase Par14 is committed to the growth of prostate cancer cells through enhancing the transcriptional activity of androgen receptor

Miki Naito

Development of reflective photoacoustic microscopy for in vivo prostate cancer CTC detection

Kazuyoshi Tachi

Initial experience of comprehensive cancer genomic profiling tests in metastatic castration-resistant prostate cancer-patients

Hideyasu Tsumura